Latest Financial Performance News

KKR Credit Income Fund has released the audited financial statements for its core investments as of December 31, 2025, revealing mixed returns and ongoing portfolio adjustments across multiple funds.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Magellan Infrastructure Fund (Currency Hedged) reported a $73.9 million profit for FY2026, down from $108.1 million the prior year, while boosting distributions to unitholders by over 270%.

Moonlight Resources Ltd (ASX: ML8) completed its first year as a listed entity, rapidly expanding its gold and copper exploration at the Clermont Project in Queensland. The company reported a net loss of $1.98 million for FY2026, reflecting active exploration and corporate growth following its December 2025 IPO.

Nanuk New World Fund posted robust gains in the 2026 financial year, with its hedged unit class surging 36.1% and unhedged units rising 27.1%, driven by a global equities portfolio focused on sustainability themes.

Dexus has delivered a 37.0 cents per security distribution for FY26, matching guidance despite economic headwinds, while initiating a strategic review of infrastructure funds acquired in 2023 and forecasting lower earnings in FY27.

BKI Investment Company has expanded its risk disclosure, outlining significant market, income, operational, and regulatory risks that could influence its financial outcomes and shareholder dividends.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Magontec Limited has reversed its recent losses with a 63% jump in half-year gross profit to $8.5 million and a net profit after tax of $1.1 million, driven by strong demand in electronic anodes and magnesium alloys.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Foley Wines reported a 258% surge in net profit for FY2026 despite a 5.4% decline in bottled sales revenue, driven by a premiumisation strategy and cost controls.